

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re	:	Chapter 11
	:	
AKORN, INC., et al., ¹	:	Case No. 20-11177 (KBO)
	:	
Debtors.	:	(Jointly Administered)
	:	Hrg. Date: 9/1/20 @ 10:00a.m.
	:	

**PROVEPHARM, INC.’S POTENTIAL WITNESS AND EXHIBIT LIST FOR HEARINGS
ON SEPTEMBER 1-3, 2020 TO CONSIDER THE SALE TRANSACTION
AND PLAN CONFIRMATION**

Provepharm, Inc. (“**Provepharm**”), respectfully submits its witness and exhibit list for the hearings currently scheduled for September 1, 2020 through September 3, 2020 (the “Hearings”) concerning the (i) *Debtors’ Motion Seeking Entry of an Order (A) Authorizing and Approving Bidding Procedures, (B) Scheduling an Auction and a Sale Hearing, (C) Approving the Form and Manner of Notice Thereof, (D) Establishing Notice and Procedures for the Assumption and Assignment of Certain Executory Contracts and Leases, and (E) Granting Related Relief* (ECF No. 18); and (ii) *Confirmation of the Modified Joint Chapter 11 Plan of Akorn, Inc. and Its Debtor Affiliates* (ECF No. 547).

WITNESS LIST

1. Any persons listed or called at the Hearings by any other party,
2. Any impeachment witness, and
3. Any rebuttal witness.

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, if any are: Akorn, Inc. (7400); 10 Edison Street LLC (7890); 13 Edison Street LLC; Advanced Vision Research, Inc. (9046); Akorn (New Jersey), Inc. (1474); Akorn Animal Health, Inc. (6645); Akorn Ophthalmics, Inc. (6266); Akorn Sales, Inc. (7866); Clover Pharmaceuticals Corp. (3735); Covenant Pharma, Inc. (0115); Hi-Tech Pharmacal Co., Inc. (8720); Inspire Pharmaceuticals, Inc. (9022); Oak Pharmaceuticals, Inc. (6647); Olta Pharmaceuticals Corp. (3621); VersaPharm Incorporated (6739); VPI Holdings Corp. (6716); and VPI Holdings Sub, LLC. The location of the Debtors’ service address is: 1925 W. Field Court, Suite 300, Lake Forest, Illinois 60045.



EXHIBITS

1. Provepharm may submit the following Exhibits at the Hearings:

Exhibit No.	Document
P-1	Akorn's 10-K EOFY 2019 (filed 2/26/20) (Akorn's Ex. 3 – in part)

2. Provepharm may also submit any exhibits included on the exhibit lists of and/or introduced at the Hearings by any other party, and

3. Any rebuttal or impeachment exhibits.

RESERVATION OF RIGHTS

Provepharm reserves the right to (a) amend or supplement the foregoing lists of witnesses and exhibits at any time prior to the Hearings; (b) use additional exhibits for purposes of rebuttal or impeachment, whether or not designated herein, and to further supplement the foregoing lists of witnesses and exhibits as necessary in connection therewith; (c) rely upon and use as evidence (i) additional documents produced by any party, (ii) exhibits included on the exhibit lists of any other party, and (iii) any pleading, hearing transcript, order, or other document filed with or by the Court in the above-captioned chapter 11 bankruptcy cases (the “**Chapter 11 Cases**”); and/or (d) request that the Court take judicial notice of any pleadings, hearing transcripts, orders, or other documents filed in the Chapter 11 Cases and/or any other related case or proceeding.

Dated: August 31, 2020

NORTON ROSE FULBRIGHT US LLP

/s/ Michael M. Parker

Michael M. Parker
michael.parker@nortonrosefulbright.com

111 W. Houston Street, Suite 1800
San Antonio, TX 78205-3792
Telephone: (210) 224-5575
Facsimile: (210) 270-7205

and

ASHBY & GEDDES

/s/ William P. Bowden

William P. Bowden (#2553)
500 Delaware Avenue, 8th Fl.
Wilmington, DE 19899
P: (302) 654-1888
F: (302) 654-2067
wbowden@ashbygeddes.com

COUNSEL FOR PROVEPHARM, INC.